source
- ArriVent BioPharma's Phase 3 lung cancer trial misses primary endpoint, shares tumbleArriVent BioPharma reported that its investigational EGFR tyrosine kinase inhibitor firmonertinib did not achieve a statistically significant improvement in progression-free survival in the Phase 3…
- Caribou Biosciences to halt R&D and cut staff as financing for allogeneic CAR-T dries upCaribou Biosciences, co‑founded by Nobel laureate Jennifer Doudna, announced it will stop all clinical‑stage work and lay off staff because of a financing freeze in the allogeneic CAR‑T market. Th…